Dendritic cell subsets and locations.

BDCA1 BDCA2 BDCA3 CDc2 DC subsets Dendritic cell LCs SIRPa XCR1 cDC1 infDC pDC

Journal

International review of cell and molecular biology
ISSN: 1937-6448
Titre abrégé: Int Rev Cell Mol Biol
Pays: Netherlands
ID NLM: 101475846

Informations de publication

Date de publication:
2019
Historique:
entrez: 8 12 2019
pubmed: 8 12 2019
medline: 16 4 2020
Statut: ppublish

Résumé

Dendritic cells (DCs) are a unique class of immune cells that act as a bridge between innate and adaptive immunity. The discovery of DCs by Cohen and Steinman in 1973 laid the foundation for DC biology, and the advances in the field identified different versions of DCs with unique properties and functions. DCs originate from hematopoietic stem cells, and their differentiation is modulated by Flt3L. They are professional antigen-presenting cells that patrol the environmental interphase, sites of infection, or infiltrate pathological tissues looking for antigens that can be used to activate effector cells. DCs are critical for the initiation of the cellular and humoral immune response and protection from infectious diseases or tumors. DCs can take up antigens using specialized surface receptors such as endocytosis receptors, phagocytosis receptors, and C type lectin receptors. Moreover, DCs are equipped with an array of extracellular and intracellular pattern recognition receptors for sensing different danger signals. Upon sensing the danger signals, DCs get activated, upregulate costimulatory molecules, produce various cytokines and chemokines, take up antigen and process it and migrate to lymph nodes where they present antigens to both CD8 and CD4 T cells. DCs are classified into different subsets based on an integrated approach considering their surface phenotype, expression of unique and conserved molecules, ontogeny, and functions. They can be broadly classified as conventional DCs consisting of two subsets (DC1 and DC2), plasmacytoid DCs, inflammatory DCs, and Langerhans cells.

Identifiants

pubmed: 31810551
pii: S1937-6448(19)30067-X
doi: 10.1016/bs.ircmb.2019.07.004
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-68

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI081848
Pays : United States

Informations de copyright

© 2019 Elsevier Inc. All rights reserved.

Auteurs

Sreekumar Balan (S)

The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address: sreekumar.balan@mssm.edu.

Mansi Saxena (M)

The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Nina Bhardwaj (N)

The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Parker Institute for Cancer Immunotherapy, San Francisco, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH